GB2568928A8 - Neuroprotective composition, preparation process thereof and medical uses thereof - Google Patents

Neuroprotective composition, preparation process thereof and medical uses thereof Download PDF

Info

Publication number
GB2568928A8
GB2568928A8 GB1720018.9A GB201720018A GB2568928A8 GB 2568928 A8 GB2568928 A8 GB 2568928A8 GB 201720018 A GB201720018 A GB 201720018A GB 2568928 A8 GB2568928 A8 GB 2568928A8
Authority
GB
United Kingdom
Prior art keywords
neuroprotective composition
stem cells
mesenchymal stem
mscs
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1720018.9A
Other versions
GB2568928A (en
GB2568928B (en
GB201720018D0 (en
Inventor
Chen Te-Fu
Wang Kuo-Chuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caire Medical Biotechnology Int Co
Original Assignee
Caire Medical Biotechnology Int Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caire Medical Biotechnology Int Co filed Critical Caire Medical Biotechnology Int Co
Priority to GB1720018.9A priority Critical patent/GB2568928B/en
Publication of GB201720018D0 publication Critical patent/GB201720018D0/en
Priority to TW107142430A priority patent/TWI694148B/en
Priority to CN201811465488.XA priority patent/CN109966317B/en
Publication of GB2568928A publication Critical patent/GB2568928A/en
Publication of GB2568928A8 publication Critical patent/GB2568928A8/en
Application granted granted Critical
Publication of GB2568928B publication Critical patent/GB2568928B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

The invention relates to a neuroprotective composition derived from mesenchymal stem cells, especially a neuroprotective composition derived from the primary culture of dental pulp mesenchymal stem cells. Processes of preparing the neuroprotective composition are claimed comprising culturing mesenchymal stem cells (MSCs) in a serum free basal culture medium for at least 3 hours to obtain a cell culture, and processing the cell culture to obtain an aqueous fraction (i.e. to produce the mesenchymal stem cell conditioned medium) with a molecular weight of no more than about 5 kDa as the neuroprotective composition. The process can use ultra-filtration or tangential flow filtration (TFF) with a molecular weight cut-off of 5 kDa to collect a filtrate passing through the filter membrane. The MSCs can be dental pulp stem cells. Compositions obtained from the aforementioned method are also claimed, along with the medical use of the compositions in the treatment of neurological diseases associated with neuronal damage, including subarachnoid haemorrhage and Parkinson’s disease.
GB1720018.9A 2017-12-01 2017-12-01 Neuroprotective composition, preparation process thereof and medical uses thereof Active GB2568928B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB1720018.9A GB2568928B (en) 2017-12-01 2017-12-01 Neuroprotective composition, preparation process thereof and medical uses thereof
TW107142430A TWI694148B (en) 2017-12-01 2018-11-28 Neuroprotective composition, preparation process thereof and medical uses thereof
CN201811465488.XA CN109966317B (en) 2017-12-01 2018-12-03 Neuroprotective composition, process for its preparation and its medical use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1720018.9A GB2568928B (en) 2017-12-01 2017-12-01 Neuroprotective composition, preparation process thereof and medical uses thereof

Publications (4)

Publication Number Publication Date
GB201720018D0 GB201720018D0 (en) 2018-01-17
GB2568928A GB2568928A (en) 2019-06-05
GB2568928A8 true GB2568928A8 (en) 2019-12-11
GB2568928B GB2568928B (en) 2023-03-08

Family

ID=60950200

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1720018.9A Active GB2568928B (en) 2017-12-01 2017-12-01 Neuroprotective composition, preparation process thereof and medical uses thereof

Country Status (3)

Country Link
CN (1) CN109966317B (en)
GB (1) GB2568928B (en)
TW (1) TWI694148B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110179827A (en) * 2019-06-27 2019-08-30 北京三有利和泽生物科技有限公司 The application of Odontogenic cysts mescenchymal stem cell
CN111467373A (en) * 2020-04-24 2020-07-31 西安交通大学 Dental pulp stem cell exosome preparation, preparation method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2578081B1 (en) * 2006-10-11 2016-03-09 The General Hospital Corporation Compositions, methods, and devices for treating liver disease
AU2009219432A1 (en) * 2008-02-28 2009-09-03 Henry Ford Health System Compositions and methods for using stromal cells to enhance treatment of central nervous system injuries
KR20130008594A (en) * 2010-03-26 2013-01-22 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 Composition for treatment of damaged part
US20160206550A1 (en) * 2013-08-29 2016-07-21 Stempeutics Research Pvt. Ltd. Stromal dells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof
KR101675123B1 (en) * 2014-06-27 2016-11-14 연세대학교 산학협력단 A Composition for Treating Ischemic Diseases or Neuroinflammatory Diseases Comprising PSA-NCAM-positive Neural Precursor Cells as Active Ingredient
CA2964163A1 (en) * 2014-11-05 2016-05-12 Tissuetech, Inc. Compositions and method for promoting nerve growth and regeneration
WO2017139795A1 (en) * 2016-02-12 2017-08-17 Cell Care Therapeutics Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
CN106967679B (en) * 2017-03-23 2021-04-13 北京恒峰铭成生物科技有限公司 Preparation method and application of high-concentration glucose solution activated mesenchymal stem cell conditioned medium

Also Published As

Publication number Publication date
CN109966317B (en) 2023-02-03
GB2568928A (en) 2019-06-05
TWI694148B (en) 2020-05-21
GB2568928B (en) 2023-03-08
TW201925463A (en) 2019-07-01
GB201720018D0 (en) 2018-01-17
CN109966317A (en) 2019-07-05

Similar Documents

Publication Publication Date Title
Song et al. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system
CN105543313A (en) Human-derived mesenchymal stem cell factor, and preparation method and application thereof
WO2016061232A3 (en) Multiplexed shrnas and uses thereof
WO2011063005A3 (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
CN103951743A (en) Human SFRP1 (secreted frizzled-related protein 1) variant and application thereof
GB2568928A8 (en) Neuroprotective composition, preparation process thereof and medical uses thereof
US20140271616A1 (en) Compositions And Methods For Mesenchymal And/Or Chondrogenic Differentiation Of Stem Cells
CN107937342A (en) A kind of method that excretion body by source of endothelial cells expands neural stem cell
CN102961741A (en) Method for preparing tetanus toxoid vaccine
KR101830803B1 (en) Method for Extracting Human Serum Albumin from Transgenic Rice Grain
CN101570565A (en) Functional component prepared from earthworms for promoting growth of microorganisms and improving culture units and preparation method thereof
MX2017000772A (en) Method for extracting soluble proteins from microalgal biomass.
JP2016210730A (en) Pharmaceutical compositions and production methods thereof as well as pharmaceuticals
KR101427102B1 (en) A Productive method of Zygotic Embryo-derived Embryogenic Cell Suspension Cultures of Camellia sinensis
Pérez-Luz et al. Altered secretome and ROS production in olfactory mucosa stem cells derived from Friedreich’s Ataxia patients
CN105087475B (en) A kind of method that cell culture fluid and its application and induction dental pulp stem cell break up to neural-like cells
AU2013403886B2 (en) Method for differentiating pluripotent stem cell induced from mesenchymal stem cell into osteoblast
CN107164325A (en) The preparation method and kit of the oligodendroglia in MSCs sources
JP6592846B2 (en) Cell reprogramming induction method and method for producing pluripotent cells
WO2014167943A1 (en) Protein-containing component for inducing cell re-programming, method for manufacturing pluripotent cells using said component, and medium comprising said component
Jiao et al. MicroRNA-26b-5p promotes development of neonatal respiratory distress syndrome by inhibiting differentiation of mesenchymal stem cells to type II of alveolar epithelial cells via regulating Wnt5a.
Jindal et al. The emerging role of stem cells in ocular neurodegeneration: hype or hope?
Wang et al. Intravenous Transplantation of Allograft hUC-MSC was More Effective Than Subarachnoid Transplantation of BM-MSCs in Patients with Parkinson's Syndrome and Secondary Parkinson's Syndrome
CN106619443A (en) Eye mask dressing and preparation method thereof
JP5770443B2 (en) Method for producing hyaluronic acid

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20221027 AND 20221102